Clearpoint Neuro Inc
CLPT13.460USD
+0.890+7.08%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
382.64MMarket Cap
LossP/E TTM
More Details of Clearpoint Neuro Inc Company
ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The Company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The Company also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.
Clearpoint Neuro Inc Info
Ticker SymbolCLPT
Company nameClearpoint Neuro Inc
IPO dateJul 03, 2019
CEOBurnett (Joseph Michael)
Number of employees115
Security typeOrdinary Share
Fiscal year-endJul 03
Address120 S. Sierra Avenue
CitySOLANA BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92075
Phone19499006833
Websitehttps://www.clearpointneuro.com/
Ticker SymbolCLPT
IPO dateJul 03, 2019
CEOBurnett (Joseph Michael)
Company Executives of Clearpoint Neuro Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Michael Burnett
Mr. Joseph Michael Burnett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
276.33K
--
Mr. Timothy T. Richards
Mr. Timothy T. Richards
Independent Director
Independent Director
79.75K
+884.00%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
Independent Director
Independent Director
50.52K
+21093.00%
Mr. Mazin Sabra
Mr. Mazin Sabra
Chief Operating Officer
Chief Operating Officer
44.47K
+386.00%
Ms. Lynnette C. Fallon
Ms. Lynnette C. Fallon
Independent Director
Independent Director
40.90K
-10200.00%
Mr. Pascal E.R. Girin
Mr. Pascal E.R. Girin
Independent Director
Independent Director
--
--
Mr. R. John Fletcher
Mr. R. John Fletcher
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. B. Kristine (Kris) Johnson
Ms. B. Kristine (Kris) Johnson
Independent Director
Independent Director
--
--
Mr. Danilo D' Alessandro
Mr. Danilo D' Alessandro
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Linda M. Liau
Dr. Linda M. Liau
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Michael Burnett
Mr. Joseph Michael Burnett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
276.33K
--
Mr. Timothy T. Richards
Mr. Timothy T. Richards
Independent Director
Independent Director
79.75K
+884.00%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
Independent Director
Independent Director
50.52K
+21093.00%
Mr. Mazin Sabra
Mr. Mazin Sabra
Chief Operating Officer
Chief Operating Officer
44.47K
+386.00%
Ms. Lynnette C. Fallon
Ms. Lynnette C. Fallon
Independent Director
Independent Director
40.90K
-10200.00%
Mr. Pascal E.R. Girin
Mr. Pascal E.R. Girin
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Products: Functional neurosurgery
3.42M
38.62%
Services: Biologics and drug delivery
3.11M
35.10%
Products: Biologics and drug delivery
1.29M
14.58%
Product Systems and software products
647.00K
7.30%
Services: Capital equipment and other
390.00K
4.40%
By RegionUSD
Name
Revenue
Proportion
United States
8.86M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Products: Functional neurosurgery
3.42M
38.62%
Services: Biologics and drug delivery
3.11M
35.10%
Products: Biologics and drug delivery
1.29M
14.58%
Product Systems and software products
647.00K
7.30%
Services: Capital equipment and other
390.00K
4.40%
Shareholding Stats
Updated: Fri, Feb 6
Updated: Fri, Feb 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
5.94%
BlackRock Institutional Trust Company, N.A.
5.47%
Bigger Capital Funds, LP
4.48%
PTC Therapeutics Inc
3.01%
Geode Capital Management, L.L.C.
2.21%
Other
78.90%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
5.94%
BlackRock Institutional Trust Company, N.A.
5.47%
Bigger Capital Funds, LP
4.48%
PTC Therapeutics Inc
3.01%
Geode Capital Management, L.L.C.
2.21%
Other
78.90%
Shareholder Types
Shareholders
Proportion
Investment Advisor
21.26%
Investment Advisor/Hedge Fund
10.48%
Hedge Fund
8.69%
Individual Investor
4.99%
Corporation
3.01%
Research Firm
1.38%
Bank and Trust
0.10%
Pension Fund
0.03%
Insurance Company
0.03%
Other
50.03%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
238
11.91M
42.82%
-795.00
2025Q3
241
11.91M
44.93%
+805.07K
2025Q2
228
11.11M
37.29%
+1.29M
2025Q1
216
9.82M
36.04%
-268.85K
2024Q4
204
9.20M
33.04%
+1.04M
2024Q3
190
8.15M
32.05%
-235.56K
2024Q2
185
8.39M
33.08%
-454.38K
2024Q1
183
8.85M
30.95%
+359.48K
2023Q4
183
7.82M
35.41%
+717.11K
2023Q3
184
7.11M
35.71%
+336.40K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
1.50M
5.03%
+22.52K
+1.53%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
1.63M
5.47%
+127.17K
+8.48%
Sep 30, 2025
Bigger Capital Funds, LP
1.29M
4.34%
+126.00K
+10.80%
Sep 30, 2025
PTC Therapeutics Inc
894.58K
3.01%
--
--
Aug 23, 2024
Geode Capital Management, L.L.C.
656.40K
2.21%
+31.60K
+5.06%
Sep 30, 2025
State Street Investment Management (US)
482.65K
1.62%
+149.27K
+44.77%
Sep 30, 2025
Two Sigma Investments, LP
442.93K
1.49%
+421.00K
+1919.91%
Sep 30, 2025
Bigger (Michael)
378.69K
1.27%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
360.70K
1.21%
+205.29K
+132.10%
Sep 30, 2025
District 2 Capital LP
307.75K
1.03%
-122.42K
-28.46%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
1.19%
iShares Neuroscience and Healthcare ETF
0.94%
iShares Micro-Cap ETF
0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
Vanguard US Momentum Factor ETF
0.06%
Motley Fool Next Index ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
iShares Russell 2000 Growth ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion1.19%
iShares Neuroscience and Healthcare ETF
Proportion0.94%
iShares Micro-Cap ETF
Proportion0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.09%
Vanguard US Momentum Factor ETF
Proportion0.06%
Motley Fool Next Index ETF
Proportion0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.03%
iShares Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
